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Purpose: To assess whether lysyl oxidase-like 1 (LOXL1) polymorphisms are associated with primary open-angle
glaucoma (POAG) and exfoliation syndrome (XFS).
Methods: Japanese patients with POAG (n=213) or XFS (n=89) and 191 control subjects were analyzed for LOXL1
polymorphisms  (rs1048661:  758G/T,  Arg141Leu  and  rs3825942:  794G/A,  Gly153Asp).  Demographic  and  clinical
features of POAG patients and control subjects were compared in terms of the TT/GG compound genotype of rs1048661
and rs3825942.
Results: There was a significant difference in the genotype frequencies between XFS patients and control subjects
(p<0.0001). Frequencies of the T allele of rs1048661 and the G allele of rs3825942 were significantly higher in XFS
patients than in control subjects (rs1048661: 99.4% versus 55.0%; rs3825942: 99.4% versus 85.3%; p<0.0001). Except
for one who had the TG/AG compound genotype, all XFS patients had the TT/GG compound genotype. An almost 250
fold increase in the risk of XFS (p<0.0001; odds ratio: 252.2; 95% confidence interval: 32.7 to more than 1000) was found
in patients with the TT/GG compound genotype compared to those without the genotype. There were no significant
differences in the genotype and allele frequencies between POAG patients and control subjects. Furthermore, no significant
differences were noted in the demographic and clinical features of POAG patients as well as control subjects with and
without the TT/GG high-risk compound genotype.
Conclusions: LOXL1 polymorphisms were associated with XFS. However, the frequencies of the polymorphisms differed
between Japanese and Caucasian XFS patients. These polymorphisms had no influence on the phenotypic features of
POAG patients.
Exfoliation  syndrome  (XFS)  is  characterized  by  the
accumulation of extracellular fibrillar materials in various
organs of the body [1,2]. In the eye, exfoliation materials
develop mainly on the lens surface, corneal endothelium, iris,
trabecular  meshwork,  zonula,  and  ciliary  body  [3].
Characteristic tissue alterations are predisposed to a broad
spectrum of intraocular complications including insufficient
mydriasis, blood-aqueous barrier dysfunction, phacodonesis,
and angle closure glaucoma [3,4]. It is said that XFS is one
cause of open-angle glaucoma. Jeng et al. [5] reported that the
15 year risk of XFS conversion into exfoliation glaucoma
(XFG) is approximately 60%. As XFG is characterized by
rapid progression, high resistance to medical therapy, and
poor  prognosis  [6],  it  is  important  to  identify  the  exact
composition  of  XFS  materials  as  well  as  the  molecular
mechanism  responsible  for  its  excessive  production  and
progressive accumulation.
Thorleifsson et al. [7], in 2007, demonstrated that two
single  nucleotide  polymorphisms  (SNPs),  rs1048661
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(R141L)  and  rs3825942  (G153D),  in  exon  1  of  the  lysyl
oxidase-like 1 (LOXL1) gene confer risk of XFG, possibly
through XFS, in patients from Iceland and Sweden. They
reported that approximately 25% of the general population
was homozygous for the highest risk haplotype and that the
risk of XFG for those 25% was more than 700 times that of
individuals  carrying  only  low  risk  haplotypes.  They  also
reported that the two SNPs in LOXL1 were not associated with
primary open-angle glaucoma (POAG). However, the LOXL1
high risk genotype for XFS may affect the phenotypic features
such as maximum intraocular pressure (IOP) of patients with
POAG. In this study, we investigated whether the two SNPs in
LOXL1 were associated with XFS and POAG in the Japanese
population. Furthermore, we also investigated in detail the
association between the two SNPs and the phenotypic features
of patients with POAG.
METHODS
Subjects: Japanese patients with POAG or XFS including
XFG  were  recruited  from  ophthalmology  practices  in  the
University  of  Yamanashi  Hospital,  Enzan  Municipal
Hospital,  Uenohara  City  Hospital,  and  Oizumi  Clinic  in
Yamanashi or Nagano Prefecture, which are all located in the
central portion of Japan (mostly the same population as that
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1303previously reported from Japan [8]). A diagnosis of POAG
was made when open angles were detected on gonioscopic
examination and typical glaucomatous cupping of the optic
disc with compatible visual field defects was detected by
automated static perimetry (Humphrey Visual Field Analyzer
30–2,  Humphrey  Instruments,  San  Leandro,  CA).
Additionally, patients were diagnosed with POAG when at
least one previous measurement of IOP with a Goldmann
applanation tonometer exceeded 21 mmHg. A diagnosis of
XFS was made when accumulation of abnormal microfibrillar
deposits on the papillary ruff with or without a grayish central
disc on the anterior lens capsule was detected in at least one
eye. Patients were excluded if they had a history of eye surgery
including laser treatment such as laser trabeculoplasty before
the diagnosis of POAG or XFS. Control subjects recruited
from the participating institutions were Japanese who were
over 40 years of age, had an IOP below 21 mmHg, exhibited
no XFS and no glaucomatous cupping of the optic disc (no
thinning of disc rim and cup-to-disc ratio less than 0.4), and
had  no  family  history  of  glaucoma.  All  subjects  received
comprehensive ophthalmologic examinations including both
slit  lamp  biomicroscopy  and  fundoscopy,  and  peripheral
blood was collected. The study protocol was approved by the
ethics  committee  of  the  University  of  Yamanashi,  and
informed consent was obtained from all study participants.
The study was conducted in accordance with the Declaration
of Helsinki.
Genomic DNA genotyping: Genomic DNA was purified with
a Flexi Gene® DNA Kit (Qiagen, Valencia, CA), and two
nonsynonymous SNPs, rs1048661 (758G/T, Arg141Leu) and
rs3825942 (794G/A, Gly153Asp), both located in exon 1 of
LOXL1,  were  genotyped  by  restriction  fragment  length
polymorphism assay. The following primers were used for
amplification: forward primer: 5′-GCT GAT CCA GTG GGA
GAA CAA-3′ and reverse primer: 5′-GGG CTG GTA GGG
GTA GAT GA-3′.
The primers amplified the DNA region that spans both
LOXL1 polymorphic sites. Amplification product (5 μl) was
digested with 4 units of Apa I (New England Biolabs, Beverly,
MA) for 2 h at 25 °C to genotype rs1048661 or digested with
4 units of Hinf I (New England Biolabs, Beverly, MA) for 2
h at 37 °C to genotype rs3825942. DNA fragments with G at
codon 141 (corresponding to an arginine residue) contained
the Apa I restriction site, resulting in fragments of 304 bp+264
bp, while DNA fragments with T at codon 141 (corresponding
to a leucine residue) lacked the Apa I restriction site, resulting
in a fragment of 568 bp. DNA fragments with A at codon 153
(corresponding to an aspartic acid residue) contained the Hinf
I restriction site, resulting in fragments of 335 bp+233 bp,
while DNA fragments with G at codon 153 (corresponding to
a glycine residue) lacked the Hinf I restriction site, resulting
in a fragment of 568 bp. After the amplification products were
loaded on 2% agarose gels and electrophoresed, the gels were
stained with ethidium bromide and genotypes were obtained
(Figure 1). To perform accurate genotyping, amplification
products were accurately genotyped by direct sequencing and
were used as positive controls for restriction fragment length
polymorphism  assay.  Arg141Leu  heterozygosity  or
Gly153Asp  heterozygosity  polymerase  chain  reaction
products  were  inserted  into  a  pGEM-T  vector  (Promega
Corporation, San Luis Obispo, CA) by TA cloning. Plasmid
DNA was amplified with the following primers: M13-forward
primer: 5′-GTA AAA CGA CGG CCA G-3′ and M13-reverse
primer: 5′-GGA AAC AGC TAT GAC CAT G-3′
After  amplification,  nucleotide  sequences  were
determined  with  a  Thermo  SequenaseTM  Primer  Cycle
Sequencing  Kit  (GE  Healthcare  Bio-Sciences,
Buckinghamshire, England) and 5′-Texas Red labeling M13-
forward  or  M13-reverse  primer.  Sequence  data  were
compared with the sequence registered in the NCBI GenBank
(NM_005576),  and  141Leu-153Gly  homozygosity  and
141Arg-153Asp homozygosity were identified and used as
positive  controls.  Heterozygosity  control  was  obtained  by
mixing these two homozygosity plasmids.
Statistical analysis: Data were analyzed using SAS statistical
software  (version  9.1,  SAS  Institute  Inc.,  Cary,  NC).  χ2
Figure 1. Electrophoresis of polymerase chain reaction-restriction
fragment length polymorphism products for detection of nucleotide
alterations of rs1048661 and rs3825942. DNA fragments with G at
codon 141 (rs1048661) contained the Apa I restriction site, resulting
in fragments of 304 bp+264 bp, while DNA fragments with T lacked
the Apa I restriction site, resulting in a fragment of 568 bp. DNA
fragments with A at codon 153 (rs3825942) contained the Hinf I
restriction site, resulting in fragments of 335 bp+233 bp, while DNA
fragments with G lacked the Hinf I restriction site, resulting in a
fragment of 568 bp. Information for rs1048661: M; 100 bp marker,
Lane 1; H2O (negative control), Lane 2; GG (positive control), Lane
3; TT (positive control), Lane 9 and 10; GG, Lane 5, 6, and 8; TG,
Lane 4 and 7; TT. Information for rs3825942: M; 100 bp marker,
Lane 1; H2O (negative control), Lane 2; AG (positive control) Lane
3; GG (positive control), Lane 5, 6, and 7; GG, Lane 4, 8, and 10;
AG, Lane 9; AA.
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genotypes was performed for patients and control subjects.
Genotype and allele frequency differences between POAG or
XFS patients and control subjects were estimated by the χ2 test
and Fisher’s exact test, respectively. Statistical analyses of the
compound  genotype  of  rs1048661  and  rs3825942  were
conducted using the χ2 test. We also used a logistic regression
model  to  simultaneously  study  the  effects  of  multiple
variables when comparing XFS patients with control subjects.
The  predictor  variables  were  age,  gender,  and  TT/GG
compound genotype of rs1048661 and rs3825942. The odds
ratio of age is per year. We also compared demographic and
clinical features including age at the time of blood sampling
and diagnosis, gender, family history of glaucoma, refractive
error, maximum IOP, and history of laser trabeculoplasty and
glaucoma surgery of control subjects and POAG patients with
and without the TT/GG compound genotype using the Student
t-test  for  continuous  variables  and  Fisher’s  exact  test  for
comparison  of  proportions.  p<0.05  was  considered  to  be
statistically significant.
RESULTS
Two hundred and thirteen Japanese patients with POAG, 89
patients with XFS (67 of 89 patients were XFG), and 191
control subjects were enrolled in this study. The mean age at
the  time  of  blood  sampling  was  62.9±14.8  (standard
deviation) years for POAG patients (range: 20–95 years),
76.5±6.6 years for XFS patients (range: 60–92 years), and
65.7±11.4 years for control subjects (range: 41–87 years). The
mean age at the time of diagnosis was 54.4±15.3 years and
70.4±8.2 years for POAG and XFS patients, respectively.
Genotype and allele frequencies of the two SNPs, rs1048661
and rs3825942, in POAG patients, XFS patients, and control
subjects are shown in Table 1. These genotype and allele
frequencies were in Hardy–Weinberg equilibrium in POAG
and  XFS  patients  and  control  subjects.  Whereas  no
statistically  significant  differences  in  genotype  and  allele
frequencies were found between POAG patients and control
subjects, a significant difference in genotype frequencies of
rs1048661 and rs3825942 was noted between XFS patients
and control subjects (p<0.0001, χ2 test). Frequencies of the T
allele  of  rs1048661  and  the  G  allele  of  rs3825942  were
significantly higher in XFS patients than in control subjects
(rs1048661: 99.4% versus 55.0%, rs3825942: 99.4% versus
85.3%,  p<0.0001,  Fisher’s  exact  test).  The  compound
genotype frequencies of these two SNPs in POAG patients,
XFS patients, and control subjects are shown in Table 2.
Except one who had the TG/AG compound genotype, all XFS
patients had the TT/GG compound genotype of rs1048661
and  rs3825942.  A  significant  difference  in  compound
genotype frequencies was noted between XFS patients and
control subjects (p<0.0001, χ2 test). After adjusting for age
and  gender,  an  almost  250  fold  increase  in  risk  of  XFS
(p<0.0001, odds ratio: 252.2, 95% confidence interval: 32.7
to more than 1000) was found in patients with the TT/GG
compound  genotype  compared  to  those  with  no  such
genotype.  No  significant  differences  were  noted  in  the
demographic and clinical features of POAG patients as well
as control subjects with and without the TT/GG compound
genotype (Table 3).
DISCUSSION
The  pathology  of  XFS  is  characterized  by  chronic
accumulation  of  abnormal  fibrillar  material.  The  current
pathogenetic  concept  describes  XFS  as  an  elastic
microfibrillopathy  (abnormal  aggregation  of  elastin
microfibrillar components) [6]. LOXL1 is a member of the
lysyl  oxidase  family  of  proteins  that  catalyzes  oxidative
deamination of lysine residues of tropoelastin, which leads to
their spontaneous cross-linking with consequent formation of
elastin polymer fibers [9,10]. Thorleifsson et al. [7] reported
that allele G was the risk allele of rs1048661 and rs3825942
for XFS, the (G, G) haplotype had the highest risk, and the
risk G allele of rs1048661 was associated with low expression
of LOXL1 mRNA, which suggests that low LOXL1 expression
predisposes  to  XFS.  Similar  frequencies  of  LOXL1  SNP
alleles,  genotypes,  and  haplotypes  were  also  reported  in
Caucasian Australian [11], American [12-16], and European
[16] populations as well as the Indian [17] population. In this
study, two SNPs, rs1048661 and rs3825942, were associated
with  XFS.  However,  the  allele,  genotype,  and  compound
genotype frequencies of these two SNPs differed between our
XFS patients and Caucasian XFS patients, as Hayashi et al.
[8] reported. We found that, except one who had the TG/AG
compound  genotype,  all  XFS  patients  had  the  TT/GG
compound genotype of rs1048661 and rs3825942 and that
allele T and not G was the risk allele of rs1048661. It is
difficult to provide an explanation why allele T of rs1048661
is  associated  with  XFS  in  the  Japanese  population  alone.
However, these data suggest that rs1048661 (R141L) may be
little related to the occurrence of XFS, and the reduced LOXL1
expression by allele G of rs1048661 may be a small change
and not necessarily biologically meaningful as Thorleifsson
et al. [7] described. In the Japanese population, it is considered
that two copies of haplotype (T, G) are in principle necessary
for the occurrence of XFS, and the T allele of rs1048661 plays
an important role as a risk allele. In our control subjects, the
frequency of T allele of rs1048661 was higher than that of G
allele, contrary to the reported allele frequencies in Caucasian
populations [7,11-16]. The prevalence of XFS in the Japanese
population over 60 years of age is 2.1% [18], which is not high
compared  to  other  ethnic  populations  such  as  the  Nordic
population  [19].  The  characteristic  allele  frequencies  of
LOXL1 may affect the low prevalence of XFS in the Japanese
population. It remains to be determined whether there are
subtypes of XFS with different patterns of manifestation. XFS
patients  in  this  study  presented  with  either  unilateral  or
bilateral involvement with or without elevated IOP. It seems
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of the genotypes of LOXL1 because most XFS patients had
the  same  compound  genotype.  Several  susceptibility  loci
[20-22] and other susceptibility genes [23,24] for XFS have
been reported. Susceptibility genes without LOXL1 may be
associated with the phenotype differences in patients with
XFS.
Signs of XFS often appear later in eyes initially diagnosed
as  having  POAG.  It  is  not  clear  whether  this  reflects  an
inaccurate clinical diagnosis or a coincidence of two different
conditions.  By  thorough  biomicroscopic  examination,  a
diffuse-matte homogeneous film that consists of a layer of
microfibrils  can  be  observed  on  the  entire  surface  of  the
anterior lens capsule before the formation of typical XFS
deposits [3]. A prospective 10 year follow up study involving
patients with clinically unilateral XFS showed that glaucoma
may develop in the contralateral eye before the emergence of
any signs of clinical XFS [25], indicating that exfoliation
materials that form before clinically typical XFS deposits may
cause  open-angle  glaucoma.  In  this  study,  although  no
statistically  significant  differences  in  genotype  and  allele
frequencies were found between POAG patients and control
subjects  as  previous  studies  have  reported  [7,15,26],
approximately 30% of POAG patients had the TT/GG high-
risk compound genotype for XFS in LOXL1. It was also found
that exfoliation materials that form before any clinical signs
of XFS may affect phenotypic features including maximum
IOP in patients with POAG. However, as shown in Table 3,
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TABLE 1. GENOTYPE   AND   ALLELE FREQUENCIES   OF   RS1048661   AND RS3825942   IN PATIENTS   WITH   PRIMARY  
OPEN ANGLE   GLAUCOMA   AND   EXFOLIATION SYNDROME   AND   CONTROL   SUBJECTS.
SNP Genotype/Allele Control (n=191)      POAG (n=213) p value* XFS** (n=89) p value*
rs1048661
(Arg141Leu)
Genotype
TT (Leu/Leu) 59 (30.9) 59 (27.7) 88 (98.9)
TG (Leu/Arg) 92 (48.2) 107 (50.2) 0.78 1 (1.1) <0.0001
GG (Arg/Arg) 40 (20.9) 47 (22.1) 0 (0)
Allele
T 210 (55.0) 225 (52.8) 0.57 177 (99.4)               <0.0001
G 172 (45.0) 201 (47.2) 1 (0.6)
rs3825942
(Gly1153Asp)
Genotype
AA (Asp/Asp) 8 (4.2) 6 (2.8) 0 (0)
AG (Asp/Gly) 40 (20.9) 52 (24.4) 0.57 1 (1.1) <0.0001
GG (Gly/Gly) 143 (74.9) 155 (72.8) 88 (98.9)
Allele
A 56 (14.7) 64 (15.0) 0.92 1 (0.6) <0.0001
G 326 (85.3) 362 (85.0) 177 (99.4)
A significant difference in genotype frequencies of  rs1048661   and  rs3825942 was noted between XFS patients and control
subjects. Frequencies of the T allele of  rs1048661 and the G allele of  rs3825942 were significantly higher in XFS patients than
in control subjects. Data are given as numbers (percentage). The asterisk indicates that the χ2 test or the Fisher's exact test was
done. The double asterisk indicates that 67of 89 XFS patients had exfoliation glaucoma. POAG: primary open angle glaucoma,
XFS: exfoliation syndrome.
TABLE 2. RS1048661 AND RS3825942 COMPOUND GENOTYPES IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA AND EXFOLIATION
SYNDROME AND CONTROL SUBJECTS.
Genotype  
rs1048661
 
T/G/
rs3825942   A/G
Control
(n=191)
POAG                                         XFS**
(n=213) p value*                 (n=89)             p value*
GG/AA 8 (4.2) 6 (2.8) 0 (0)
GG/AG 14 (7.3) 15 (7.0) 0 (0)
GG/GG 18 (9.4) 26 (12.2)         0.76                        0 (0) < 0.0001
TG/AG 26 (13.6) 37 (17.4) 1 (1.1)
TG/GG 66 (34.6) 70 (32.9) 0 (0)
TT/GG 59 (30.9) 59 (27.7) 88 (98.9)
A significant difference in compound genotype frequencies was noted between XFS patients and control subjects. Data are
given  as numbers (percentage). The asterisk indicates that the χ2 test was done. The double asterisk indicates that 67 of 89 XFS
patients had exfoliation glaucoma. POAG: primary open-angle glaucoma, XFS: exfoliation syndrome.there  were  no  significant  differences  in  demographic  and
clinical features of POAG patients as well as control subjects
with and without the TT/GG high-risk compound genotype,
and this high-risk compound genotype was not associated
with phenotypic features in patients with POAG. These results
do  not  support  the  idea  that  exfoliation  materials  formed
before any clinical signs of XFS are a cause of open-angle
glaucoma and may indicate that exfoliation materials have
little or no influence on the occurrence of POAG. In patients
with the TT/GG high-risk compound genotype, mean ages at
the time of blood sampling in control subjects and POAG
patients were significantly younger than that in XFS patients.
Some of these control subjects and POAG patients with the
TT/GG  compound  genotype  may  present  with  clinically
apparent XFS in the future because XFS is an age-related
disorder.
In conclusion, LOXL1 polymorphisms were associated
with  XFS.  However,  the  allele,  genotype,  and  compound
genotype frequencies of these two SNPs differed between
Japanese XFS patients and Caucasian XFS patients. These
polymorphisms had no influence on the phenotypic feature of
POAG patients. Further studies in the other ethnic populations
should be performed to clarify how changes of LOXL1 lead
to XFS.
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